Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Barrett

Gastroenterology Milton, MA Medical Doctor

NPI 1659549590 CMS profile 865824

100 Highland St, Ste 101, Milton, MA 02186

Open in the dashboard

General payments

$36,791

222 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Barrett of Milton, MA is reported in the CMS Open Payments database as having received $36,791 across 222 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,719 38
2024 General $8,151 31
2023 General $2,651 37
2022 General $5,740 42
2021 General $12,986 41
2020 General $3,331 22
2019 General $1,215 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Barrett
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to George Barrett were reported at $2,719. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year George Barrett Gastroenterology median Middle half National median
2019 $1,215 $417 $126–$1,100 $163
2020 $3,331 $224 $74–$624 $114
2021 $12,986 $352 $106–$1,054 $132
2022 $5,740 $448 $129–$1,270 $149
2023 $2,651 $533 $150–$1,390 $160
2024 $8,151 $605 $160–$1,606 $164
2025 $2,719 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. RedHill Biopharma Inc. $17,567 31 payments
  2. Phathom Pharmaceuticals, Inc. $9,610 16 payments
  3. Nestle HealthCare Nutrition Inc. $4,709 15 payments
  4. Romark Laboratories, LC $1,273 6 payments
  5. AbbVie, Inc. $958 45 payments
  6. Janssen Biotech, Inc. $399 17 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $387 13 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $334 17 payments
  9. QOL Medical, LLC $233 19 payments
  10. Neurocrine Biosciences, Inc. $158 3 payments
  11. Other $1,163 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $28,565 22 payments
  2. Food and Beverage $5,672 197 payments
  3. Consulting Fee $1,600 2 payments
  4. Travel and Lodging $955 1 payment
Products named General payments · program years 2019–2025
  1. Talicia $16,967 30 payments
  2. VOQUEZNA $9,579 14 payments
  3. ZENPEP $4,750 17 payments
  4. ALINIA Gastroenterology $1,273 6 payments
  5. ALINIA Gastroenterology $1,273 6 payments
  6. ALINIA Gastroenterology $1,273 6 payments
  7. CREON $768 38 payments
  8. LINZESS $681 33 payments
  9. XIFAXAN $321 16 payments
  10. TREMFYA $286 12 payments
  11. Other $2,293 110 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

1,022

Median for Gastroenterology: 569

Drug cost

$74,869

Median for Gastroenterology: $104,976

Branded share of claims

2.3%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 24 $25,010
Vancomycin Hcl Generic 88 $24,058
Omeprazole Generic 577 $13,562
Mesalamine Generic 13 $4,461
Pantoprazole Sodium Generic 167 $3,792
Sucralfate Generic 43 $1,313
Sulfasalazine Generic 15 $1,042
Colestipol Hcl Generic 12 $504
Dicyclomine Hcl Generic 32 $435
Metronidazole Generic 21 $266

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$93,663

Medicare's payments for the services billed

Medicare patients

460

Average age 74

Services billed

669

262 women, 198 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 49%
Diabetes 27%
Ischemic heart disease 25%
Cancer 20%
Atrial fibrillation 18%
Chronic kidney disease 17%
Depression 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $7,722
$7,722 — —
CREON
  • AbbVie, Inc. $75
$75 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $33
  • GENZYME CORPORATION $23
$56 — —
STELARA
  • Janssen Biotech, Inc. $54
$54 — —
EOHILIA
  • Takeda Pharmaceuticals U.S.A., Inc. $53
$53 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

222 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record